Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 Feb;106(3):217-225.
doi: 10.1002/bjs.10995. Epub 2018 Oct 11.

Development and validation of a nomogram to predict recurrence and melanoma-specific mortality in patients with negative sentinel lymph nodes

Affiliations
Multicenter Study

Development and validation of a nomogram to predict recurrence and melanoma-specific mortality in patients with negative sentinel lymph nodes

D Verver et al. Br J Surg. 2019 Feb.

Abstract

Background: Patients with melanoma and negative sentinel nodes (SNs) have varying outcomes, dependent on several prognostic factors. Considering all these factors in a prediction model might aid in identifying patients who could benefit from a personalized treatment strategy. The objective was to construct and validate a nomogram for recurrence and melanoma-specific mortality (MSM) in patients with melanoma and negative SNs.

Methods: A total of 3220 patients with negative SNs were identified from a cohort of 4124 patients from four EORTC Melanoma Group centres who underwent sentinel lymph node biopsy. Prognostic factors for recurrence and MSM were studied with Cox regression analysis. Significant factors were incorporated in the models. Performance was assessed by discrimination (c-index) and calibration in cross-validation across the four centres. A nomogram was developed for graphical presentation.

Results: There were 3180 eligible patients. The final prediction model for recurrence and the calibrated model for MSM included three independent prognostic factors: ulceration, anatomical location and Breslow thickness. The c-index was 0·74 for recurrence and 0·76 for the calibrated MSM model. Cross-validation across the four centres showed reasonable model performance. A nomogram was developed based on these models. One-third of the patients had a 5-year recurrence probability of 8·2 per cent or less, and one-third had a recurrence probability of 23·0 per cent or more.

Conclusion: A nomogram for predicting recurrence and MSM in patients with melanoma and negative SNs was constructed and validated. It could provide personalized estimates useful for tailoring surveillance strategies (reduce or increase intensity), and selection of patients for adjuvant therapy or clinical trials.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The curves refer to predicted recurrence or melanoma‐specific mortality (MSM) at 5 years. The histogram refers to the risk score distribution in the cohort; each bar represents the proportion of patients in the cohort that was assigned that specific score. The histogram was divided in tertiles: light pink bars, first tertile (low risk); medium pink bars, second tertile (intermediate risk); dark pink bars, third tertile (high risk). The nomogram incorporates three factors: ulceration, anatomical location and Breslow thickness. To calculate an individual's probability of 5‐year recurrence and MSM, values for the prognostic factors must be determined first (for example: ulceration; leg; Breslow thickness 2·5 mm). Second, for each value the corresponding points can be obtained by drawing a line from each value towards the points axis (in example: 2, 1 and 7 points respectively). Third, the points must be added up to obtain the total risk score (in example: risk score of 10). Finally, the 5‐year recurrence and MSM probability can be read by moving vertically from the x‐axis (total risk score) to the predicted risk curves and corresponding probabilities on the left y‐axis (for example: 23·0 per cent for recurrence and 11·0 per cent for MSM). The percentage of patients in the entire population (3180) that also had a total risk score of 10 can be determined from the histogram, as well as the corresponding percentage of patients on the right y‐axis (for example: 17·5 per cent)

Similar articles

Cited by

References

    1. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK et al Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392–399. - PubMed
    1. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N et al Prognostic factors analysis of 17 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622–3634. - PubMed
    1. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF et al Final trial report of sentinel‐node biopsy versus nodal observation in melanoma. N Engl J Med 2014; 370: 599–609. - PMC - PubMed
    1. Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C et al Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG‐SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 2016; 17: 757–767. - PubMed
    1. Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS et al Completion dissection or observation for sentinel‐node metastasis in melanoma. N Engl J Med 2017; 376: 2211–2222. - PMC - PubMed